BTK and B-cell chronic lymphocytic leukemia: The treatment landscape of chronic lymphocytic leukemia (CLL) has been reshaped over the past decade, largely due to the approval of small molecule inhibitors targeting Bruton’s tyrosine kinase (BTK) and the anti‐apoptotic protein B‐cell lymphoma 2 (BCL2).